Back to results
US 12,708,665 B2Granted
Anti-IL-1β antibody therapy in arrhythmogenic cardiomyopathy (ACM)
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorJeffrey E. Saffitz
Life of this patent
Estimating the term…
Abstract
Described herein are, inter alia, methods for treating arrhythmogenic cardiomyopathy (ACM) using anti-inflammatory agents that IL-1β.
Claims7
A method of treating a human subject with arrhythmogenic cardiomyopathy (ACM), the method comprising:
- (a) identifying a human subject as having or at risk of developing ACM;
- and
- (b) administering to the human subject a therapeutically effective amount of an anti-interleukin-1β (IL-1β) antibody selected from the group consisting of canakinumab, APX002, and XOMA052.
Dependencies are inferred from the claim text.